ESCMID Global 2025: Initial ABI-5366 data supports monthly dosing for genital herpes
Early clinical and preclinical findings presented at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference …
Post
-
-
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed …
-
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS
Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial …
-
Redefining the future of clinical trials in oncology
Next month, experts from big and small pharmaceutical and biotech companies, contract research organisations (CROs), cancer counselling and resource centers …
-
Akeso and Summit notch another Phase III win with their Keytruda competitor
Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary endpoint in a Phase …
-
Cytovation secures $6m for trial of CY-101 to treat adrenocortical carcinoma
Norwegian company Cytovation has secured Nkr62m ($6m) to progress CY-101 into a multi-national Phase II trial, targeting individuals with adrenocortical …
-
7 key questions to consider for your next IND filing
When preparing for an upcoming drug development program, leveraging existing knowledge and strategies to streamline the process from concept to …
-
Lokavant launches Spectrum v15 trial forecasting solution
Lokavant has launched the AI-powered clinical trial forecasting solution, Spectrum v15, to dispel uncertainty in the feasibility of studies. The solution …
-
ESCMID Global 2025: Gepotidacin is non-inferior to leading gonorrhoea dual therapy
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, Dr Janet Wilson …
-
WHO publishes first-ever guidelines for meningitis diagnosis and care
Meningitis is a life-threatening condition caused by a bacterial or viral infection. Meningitis is an infection of the protective membranes …
-
Synthetic hormones and the future of contraception
The landscape of contraception for women has seen minimal change over the past 50 years, with successive generations often relying …
-
Cellphire Therapeutics halts enrolment in trial of CLPH-511 after IDMC feedback
US-based biotechnology company Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an independent …
-
Ascletis’ oral GLP-1RA shows weight loss potential in early trial
Ascletis has announced its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved early weight loss in a Phase Ib trial …
-
Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052
The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris Therapeutics, allowing the …
-
Trump tariffs: World trade ‘fragmenting into blocks’
Catalysed by the sweeping tariffs agenda being implemented by President Donald Trump's administration in the US, the era of “easy …
